/ ABT
/ Market Analysis
Exact Sciences Spikes After Abbott Reveals Massive $23B Buyout Agreement
Exact Sciences surged more than 17% premarket after Abbott announced a $23 billion buyout, adding Cologuard and Oncotype DX to its diagnostics lineup.
November 20, 2025
Abbott Laboratories Reports Strong First Quarter Results, Maintains Positive Outlook
Abbott Laboratories reported a strong start to 2025 with significant growth in sales and EPS, exceeding market expectations.
April 16, 2025
Abbott Reports Strong Third-Quarter Performance with a 4.9% Increase in Worldwide Sales
Abbott Laboratories reported a strong third-quarter performance in 2024.
October 16, 2024
Abbott Laboratories Reports Strong Q2, Beating EPS and Revenue Forecasts
Abbott Laboratories (NYSE: ABT) reported sales of $10.4 billion in the second quarter of 2024, reflecting a 4.0% increase from the same period last year.
July 18, 2024
Abbott (ABT) Beats Q1 Expectations with $10 Billion in Sales, $0.98 EPS
Abbott has reported a strong start to the year with sales reaching $10.0 billion in Q1, driven by a 10.8 percent increase in organic sales growth.
April 17, 2024More from The Tokenist / ABT
Back to 
